$HCM News

HUTCHMED (China) Limited 2026 Q2 - Results - Earnings Call Presentation

HUTCHMED (China) H1 EPS $0.09 Down From $2.61 YoY, Sales $278.287M Up From $277.677M YoY

Goldman Sachs Maintains Neutral on HUTCHMED (China), Lowers Price Target to $14

Hutchmed: Bullish On Their Commercial Prospects And Pipeline Catalysts

B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $17

HUTCHMED's Experimental Drug Shows Durable Responses In Advanced Bile Duct Cancer Trial

Reported Earlier, HUTCHMED's Fanregratinib Achieves 42.5% Objective Response Rate In Pivotal Phase II Study For Intrahepatic Cholangiocarcinoma With FGFR2 Fusions

Reported Earlier, HUTCHMED Says Sovleplenib Shows Favorable Safety Profile With Fewer Grade 3 Adverse Events Than Placebo

Why HUTCHMED (China) Limited (HCM) Is Gaining Attention After China Biotech Re-Rating

Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

HUTCHMED And Innovent Biologics Announce That The Joint New Drug Application For The Combination Of Elunate And Tyvyt Has Been Granted Approval By The China National Medical Products Administration

HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

China Authority Accepts And Grants Priority Review To Hutchmed's Sovleplenib For Warm Antibody Autoimmune Hemolytic Anemia Patients Who Have Had An Insufficient Response To Prior Glucocorticoid Treatment

Reported Earlier, HUTCHMED Highlights HMPL-A580 Anti-Tumor Activity And Surufatinib Combination Therapy Data Ahead Of AACR Annual Meeting 2026 Presentations In San Diego

Reported Earlier, HUTCHMED Highlights HMPL-A580 Anti-Tumor Activity And Surufatinib Combination Therapy Data Ahead Of AACR Annual Meeting 2026 Presentations In San Diego

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026

Should You Be Adding HUTCHMED (China) (LON:HCM) To Your Watchlist Today?

Reported Sunday, HUTCHMED Launches Phase III Clinical Trial Of Third-Generation BTK Inhibitor HMPL-760 With R-GemOx In Chinese Relapsed/Refractory Diffuse Large B-cell Lymphoma Patients

HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China